Singapore markets closed

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
12.45+0.09 (+0.73%)
As of 09:49AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 3.45B
Enterprise value 3.25B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.44k
Price/book (mrq)5.90
Enterprise value/revenue 2.73k
Enterprise value/EBITDA -7.60

Trading information

Stock price history

Beta (5Y monthly) 0.59
52-week change 3112.74%
S&P500 52-week change 323.42%
52-week high 318.33
52-week low 33.21
50-day moving average 313.38
200-day moving average 38.03

Share statistics

Avg vol (3-month) 39.25M
Avg vol (10-day) 34.43M
Shares outstanding 5279.31M
Implied shares outstanding 6279.31M
Float 8210.92M
% held by insiders 10.56%
% held by institutions 189.18%
Shares short (28 Mar 2024) 446.38M
Short ratio (28 Mar 2024) 45.58
Short % of float (28 Mar 2024) 417.93%
Short % of shares outstanding (28 Mar 2024) 416.60%
Shares short (prior month 29 Feb 2024) 446.71M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:100
Last split date 326 Sept 2013

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-25,156.85%

Management effectiveness

Return on assets (ttm)-39.86%
Return on equity (ttm)-81.91%

Income statement

Revenue (ttm)1.19M
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -449.01M
Net income avi to common (ttm)-444.04M
Diluted EPS (ttm)-1.89
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)279.87M
Total cash per share (mrq)1
Total debt (mrq)75.86M
Total debt/equity (mrq)12.98%
Current ratio (mrq)2.79
Book value per share (mrq)2.28

Cash flow statement

Operating cash flow (ttm)-361.82M
Levered free cash flow (ttm)-211.47M